Cargando…

Minimally invasive local therapies for liver cancer

Primary and metastatic liver tumors are an increasing global health problem, with hepatocellular carcinoma (HCC) now being the third leading cause of cancer-related mortality worldwide. Systemic treatment options for HCC remain limited, with Sorafenib as the only prospectively validated agent shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, David, Kang, Josephine, Golas, Benjamin J., Yeung, Vincent W., Madoff, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296086/
https://www.ncbi.nlm.nih.gov/pubmed/25610708
http://dx.doi.org/10.7497/j.issn.2095-3941.2014.04.001
_version_ 1782352929816051712
author Li, David
Kang, Josephine
Golas, Benjamin J.
Yeung, Vincent W.
Madoff, David C.
author_facet Li, David
Kang, Josephine
Golas, Benjamin J.
Yeung, Vincent W.
Madoff, David C.
author_sort Li, David
collection PubMed
description Primary and metastatic liver tumors are an increasing global health problem, with hepatocellular carcinoma (HCC) now being the third leading cause of cancer-related mortality worldwide. Systemic treatment options for HCC remain limited, with Sorafenib as the only prospectively validated agent shown to increase overall survival. Surgical resection and/or transplantation, locally ablative therapies and regional or locoregional therapies have filled the gap in liver tumor treatments, providing improved survival outcomes for both primary and metastatic tumors. Minimally invasive local therapies have an increasing role in the treatment of both primary and metastatic liver tumors. For patients with low volume disease, these therapies have now been established into consensus practice guidelines. This review highlights technical aspects and outcomes of commonly utilized, minimally invasive local therapies including laparoscopic liver resection (LLR), radiofrequency ablation (RFA), microwave ablation (MWA), high-intensity focused ultrasound (HIFU), irreversible electroporation (IRE), and stereotactic body radiation therapy (SBRT). In addition, the role of combination treatment strategies utilizing these minimally invasive techniques is reviewed.
format Online
Article
Text
id pubmed-4296086
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Chinese Anti-Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-42960862015-01-21 Minimally invasive local therapies for liver cancer Li, David Kang, Josephine Golas, Benjamin J. Yeung, Vincent W. Madoff, David C. Cancer Biol Med Review Primary and metastatic liver tumors are an increasing global health problem, with hepatocellular carcinoma (HCC) now being the third leading cause of cancer-related mortality worldwide. Systemic treatment options for HCC remain limited, with Sorafenib as the only prospectively validated agent shown to increase overall survival. Surgical resection and/or transplantation, locally ablative therapies and regional or locoregional therapies have filled the gap in liver tumor treatments, providing improved survival outcomes for both primary and metastatic tumors. Minimally invasive local therapies have an increasing role in the treatment of both primary and metastatic liver tumors. For patients with low volume disease, these therapies have now been established into consensus practice guidelines. This review highlights technical aspects and outcomes of commonly utilized, minimally invasive local therapies including laparoscopic liver resection (LLR), radiofrequency ablation (RFA), microwave ablation (MWA), high-intensity focused ultrasound (HIFU), irreversible electroporation (IRE), and stereotactic body radiation therapy (SBRT). In addition, the role of combination treatment strategies utilizing these minimally invasive techniques is reviewed. Chinese Anti-Cancer Association 2014-12 /pmc/articles/PMC4296086/ /pubmed/25610708 http://dx.doi.org/10.7497/j.issn.2095-3941.2014.04.001 Text en 2015 Cancer Biology & Medicine This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/
spellingShingle Review
Li, David
Kang, Josephine
Golas, Benjamin J.
Yeung, Vincent W.
Madoff, David C.
Minimally invasive local therapies for liver cancer
title Minimally invasive local therapies for liver cancer
title_full Minimally invasive local therapies for liver cancer
title_fullStr Minimally invasive local therapies for liver cancer
title_full_unstemmed Minimally invasive local therapies for liver cancer
title_short Minimally invasive local therapies for liver cancer
title_sort minimally invasive local therapies for liver cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296086/
https://www.ncbi.nlm.nih.gov/pubmed/25610708
http://dx.doi.org/10.7497/j.issn.2095-3941.2014.04.001
work_keys_str_mv AT lidavid minimallyinvasivelocaltherapiesforlivercancer
AT kangjosephine minimallyinvasivelocaltherapiesforlivercancer
AT golasbenjaminj minimallyinvasivelocaltherapiesforlivercancer
AT yeungvincentw minimallyinvasivelocaltherapiesforlivercancer
AT madoffdavidc minimallyinvasivelocaltherapiesforlivercancer